HSF1) Are Associated with Poor Prognosis in Breast Cancer
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer Sandro Santagataa,b, Rong Huc,d, Nancy U. Line, Marc L. Mendillob, Laura C. Collinsf, Susan E. Hankinsonc,d, Stuart J. Schnittf, Luke Whitesellb, Rulla M. Tamimic,d,1, Susan Lindquistb,g,1, and Tan A. Inceh,1 aDepartment of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; bWhitehead Institute for Biomedical Research, Cambridge, MA 02142; cDepartment of Epidemiology, Harvard School of Public Health, Boston, MA 02115; dChanning Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; eDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; fDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115; gHoward Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and hDepartment of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136 Contributed by Susan Lindquist, September 13, 2011 (sent for review July 23, 2011) Heat-shock factor 1 (HSF1) is the master transcriptional regulator lows tumors to reconfigure their metabolism, physiology, and of the cellular response to heat and a wide variety of other stres- protein homeostasis networks to enable oncogenesis. The ulti- sors. We previously reported that HSF1 promotes the survival and mate result is the enhanced proliferation and increased fitness of proliferation of malignant cells. At this time, however, the clinical malignant cells as they emerge (6, 9, 10).
[Show full text]